<DOC>
	<DOC>NCT01241669</DOC>
	<brief_summary>This is a drug-drug interaction study to evaluate the effects of steady-state exposure of E5555 and its main metabolites on the pharmacokinetics (PK) of metformin, an organic cation transporter-2 (OCT2) substrate. In addition, the study will also investigate the effects of E5555 on several renal function parameters.</brief_summary>
	<brief_title>Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male or female subjects aged greater than or equal to 18 years to 55 years History of any medical condition which will result in an increased risk of bleeding including but not limited to active or recurrent gastric ulcers, recent head trauma or surgery, severe hypertension, bacterial endocarditis, etc. Creatinine clearance &lt; 90 mL/min as estimated using CockcroftGault formula at screening or baseline History of any renal disorders, proteinuria, hepatobiliary disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>